TREM1 and breast carcinoma: TREM-1 functional studies that take advantage of TREM-1-activating antibodies (101, 102) and inhibitory peptides (44, 52) in the context of murine immuno-oncology models will be necessary to test the hypotheses presented here, and to establish the therapeutic value of targeting TREM-1 in the clinical management of breast cancer.